Introduction
Results sQTL Distribute Throughout the Genome FVB/NJ mice transgenic for TH-MYCN were backcrossed to wild-type 129/SVJ mice, and the N1 generation (n=102) was profiled on Affymetrix Exon Arrays and genotyped at 349 SNP and microsatellite markers. We identified 1664 and 1751 sQTL (defined here as a paired alternative splicing event associated with a marker, as markers may have multiple associations -see Methods) in cerebellum (CB) and superior cervical ganglia (SCG), representing peripheral neural crest-and brain-derived tissues, respectively (Figures 1A and 1B, 5% false detection rate). The low density of our genotyping panel reflects the controlled genetic heterogeneity of our backcrossed cohort and was not intended to identify causative polymorphisms. Instead, the resulting genetic map allowed us to distinguish splicing events with local cis effects from those with distal trans effects. The majority of sQTL was within 50 Mb of the spliced transcript, and thus defined to be cis (90.3% in CB and 92.5% in SCG, Supplemental Tables 1 and   2 ). Of these cis-sQTL, 874 reflected similar splicing events in both CB and SCG whereas only 5 trans-sQTL Table 3 ). The polymorphisms of both of these types of sQTL associate with strain-specific alternative splicing events, suggesting different possible functional roles.
Trans-sQTL could represent polymorphisms within genes that influence the splicing pathway, which can then affect the splicing of other transcripts derived from a distal genomic region. Conversely, cis-sQTL represent polymorphisms at or near the gene being spliced that can directly alter canonical splice sites or create novel transcriptional start sites, cryptic splice sites, and polyadenylation signals. These cis-sQTL polymorphisms could also reside in functional regions where they can affect the ability of intronic splicing enhancers (ISEs), intronic splicing silencers (ISSs), and their exonic counterparts, ESEs/ESSs to recruit accessory splicing factors to mediate alternative splicing. 
Trans-sQTL Identify Genes that Influence Splicing
Trans-eQTL have become powerful tools to identify transcription factors (18) and other functional elements (19) , as these function in trans to regulate transcription or translation of other genes. We therefore looked at putative trans-sQTL to identify novel regulators that could affect splicing of distant genes. If master regulators of splicing were subject to genetic control, we would expect to find a high degree of co-localization, whereby the majority of trans-sQTL (with alternatively spliced exons spread throughout the genome) would associate with just a few genomic loci. Instead, we found that transsQTL were scattered throughout the genome (Figure 2A) , with little overlap at any individual genomic locus. We observed a maximum of eight co-localizing trans-sQTL and only a few "hotspots," or individual loci linked to several splicing events (≥4, Figure 2B ). We focused on two of these hotspots to simplify our efforts to validate genes that influence splicing. Specifically, we focused on the 5 trans-sQTL linked to the marker rs29347557 on chromosome 10 in SCG and the 8 trans-sQTL linked to the marker rs33477935 on the X chromosome in CB.
Candidate genes in these regions were identified by examining differential transcript expression between SCG and CB ( Figure 2B ). Given the overwhelming tissue-specific nature of the trans-sQTL, we hypothesized their origin to be from tissue-specific regulation of putative splicing-related genes in these regions. The minimal overlapping 95% confidence interval for sQTL mapping to rs29347557 in SCG encompassed the range between markers rs13480474 and rs38621064 on chromosome 10. This region spans over 13 Mb and contains 66 known genes, of which 30 were differentially expressed between CB and SCG (Supplemental Table 4 ). Almost all of these genes had known functions. Among these, Sf3b5 encodes a splicing factor subunit (20) and was the only gene known to function within the splicing pathway, supporting the idea that differentially expressed splicing machinery would reside in these loci ( Figure 2B ). The sQTL mapping to rs33477935 in CB possessed 95% confidence intervals that minimally overlapped from rs33478059 to rs13483805 on the X chromosome. This region spans over 77 Mb and contains 489 known genes, 123 of which were differentially expressed (Supplemental Table 5 ). Two of these genes are known splicing factors, Hnrnpa3 (21) , and Rbm10 (22) . Others, such as Rbmx, are also implicated in this pathway. We identified putative candidate genes Rbmx2, which contains an RNAbinding motif, and Ddx26b, which contains a DEAD-box domain. Both of these genes are relatively uncharacterized ( Figure 2B ).
To examine the role these genes could play within the splicing pathway and to extend these results into a human setting, we used siRNA to knock down DDX26B and RBMX2 in HEK293T cells (Supplemental Figure S1A ) and looked for splicing differences in the orthologous human genes associated with the colocalized trans-sQTL, by RT-PCR. We looked specifically for alternative products by eliminating amplification of the canonical isoform. Cloning and sequencing of RT-PCR products from five of these eight targets did not support any changes in splicing patterns (Ccnb2, Cdc123, Fbxl13, Ndufv2, Saps2, data not shown), whereas C5 (orthologous to AI182371) and FBXW12 (orthologous to Fbxw15) indicated changes in splicing following knockdown (Supplemental Table 4 and Supplemental Figure S1B -we were unable to investigate the final target due to the lack of annotation). While it appeared that knockdown of DDX26B and RBMX2 both affected the RT-PCR profile of C5, we examined all potential alternative products and discarded those arising from non-specific priming. Specifically in the presence of siRNA directed towards RBMX2, we identified a novel splice isoform of C5 lacking six internal exons (Supplemental Figure S1C) . Similarly, a previously undescribed splice isoform of FBXW12 lacking an internal exon was expressed only when DDX26B was knocked down (Supplemental Figure S1D ). These isoforms were undetected in the presence of non-targeting control siRNA. These data support functional roles for DDX26B and RBMX2 within the splicing pathway. We did not identify a statistically significant difference in Ddx26b or Rbmx2 expression between the parental mouse strains (Supplemental Figure S1E) , suggesting that the difference in their abilities to affect splicing does not lie at the transcriptional level.
Cis-sQTL Identify Strain-Specific Isoforms
In both CB and SCG, a cis-sQTL identified strain-specific isoform expression of fifth exon within the Astroactin 2 (Astn2) gene. This was associated with a LOD score of 65.1 at rs13477756 (Supplemental Figures S2A and B) , the highest observed in CB. Astn2 may function in neuronal migration, and exonic deletions have been identified in patients with schizophrenia (23). RT-PCR on cDNA derived from CB in both parental strains confirmed that 129/SvJ mice specifically expressed a transcript resulting from exon skipping of the fifth exon (Supplemental Figures S2C and D) .
We examined whole genome sequence information for parental FVB/NJ (24) and 129/SvJ (25) at the Astn2 locus, which revealed a lack of coverage throughout exon 5 specifically in 129/SvJ, leading us to hypothesize that this alternative isoform could result from structural variation between the two strains.
Indeed, a ~30 kb deletion present in 129/SvJ, but not in FVB/NJ, co-localized with ASTN2 and encompassed the entirety of exon 5 (Supplemental Figure S2E) . After excluding the X chromosome due to the mixed source for the 129/SvJ WGS, we further identified 1,324 somatic copy number variations (SCNVs) in 129/SvJ mice and 1,802 SCNVs in FVB/NJ compared to the reference genome (Supplemental Figure S3A and S3B). Fifty-five of these co-localized with cis-sQTL-identified alternative splicing events in 129/SvJ and fifty-eight co-localized in FVB/NJ, with 38 shared between strains (Supplemental Table 6 ).
Expression of the alternative isoform in 129/SvJ is thus a result from genomic structural variation closely linked to the rs13477756 marker. Despite this alternative mechanism, this sensitive detection of strainspecific exon usage in Astn2 by a SNP marker residing over 2 MB away from the gene itself is a clear proof of principle for our sQTL method.
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The highest LOD score observed in SCG (LOD=73.9) belonged to the FUSE-Binding Protein 1 (Fubp1) gene ( Figure 3A ). Fubp1 is a transcription factor that binds the Far Upstream Element (FUSE), thereby regulating transcription of MYC (26, 27) . Given the identification of cancer-associated somatic mutations in FUBP1 (28) and the known importance of MYC proteins in neuroblastoma (29), we further explored Fubp1. Although array data indicated a strain-specific splicing difference at the fifth exon ( Figure 3B ), complete skipping of this exon was not detected by RT-PCR (Supplemental Figure S4) . We therefore explored other models through which splicing could modulate Fubp1 activity. Exon 5 within Fubp1 is a known site of triplet NAGNAG splicing (30) , which occurs at the terminal end of 3' splice sites. This repetition includes the highly conserved AG dinucleotide that defines the intron-exon boundary, resulting in alternative 3' splice-sites that differ by three bases that are referred to by their respective intron lengths. For Fubp1, this splicing event incorporates a serine at position 97 in the proximal isoform (shorter intron, Fubp1 97S ) that is absent in the distal (longer intron, Fubp1 97-) ( Figure 3C ). Expression analyses of these isoforms across several tissue types suggests that this splicing event is not a stochastic process, but rather subject to an as-yet-undefined regulatory mechanism.
Gene-level expression datasets supported tumor suppressive effects of FUBP1 in human neuroblastoma, as higher expression correlated with better survival in all stages (31) (p=1.48x10 -4 , FDR=2.70x10 -3 , Supplemental Figure S5A ) and event-free survival in a MYCN non-amplified cohort (32) (p=7.48x10 -8 , FDR=6.51x10 -6 , Supplemental Figure S5B Figure 3E ), consistent with deregulation of triplet splicing within exon 5 of FUBP1 having a functional effect.
Splicing Motifs Serve as Sites of Recurrent Mutations in Cancer
Our genotyping marker set was not designed to identify functional polymorphisms. Rather, markers were selected to map chromosomal regions to either parental strain. As cis-sQTL represent differences in splicing driven by local genetic polymorphisms, we compared whole genome sequence information for FVB/NJ (24) and 129/SvJ (25) surrounding alternatively spliced exons possessing cis-sQTL in both tissues, identifying recurrent intronic decamer motifs that spanned the SNP. Enrichment analysis of these sequences identified 22 unique motifs (E-Value < 0.05, Supplemental Figure S6 ). Seven were similar to previously described motifs, with six known to bind splicing factors (Supplemental Figure S7 , FDR < 0.05) (36) . Thus, our method identified motifs associated with regulation of alternative splicing.
Collectively, these motifs matched 0.07% of all possible decamer sequence permutations. Despite this low rate, our position-agnostic approach identified an abundance of splicing motifs in both mouse and human introns (94.7% of murine introns and 95.2% of human introns harbored at least one of these splicing motifs), leading us to hypothesize that these splicing motifs could be functionally conserved in humans, regardless of their relative intronic positions. It has also been estimated that as much as 87%
Research. Figures 4A-C, respectively) . For DYNLRB1 and the chr7:141943454 splicing motif mutation in MOXD2P, these mutations resulted in a stronger match to a splicing motif by replacing a base found infrequently (or not at all) to a base more commonly associated with the motif. In the case of CGB7 and the chr7:141944631 splicing motif mutation in MOXD2P, the motif is effectively destroyed by substituting in a base that is not normally found.
The low incidence of recurrent genes with splicing motif mutations was unsurprising, given the low mutation rate in neuroblastoma (7) . We similarly analyzed whole-genome sequencing from 42 high-risk glioblastoma (GBM) tumors, each also with a paired normal sample (39, 40) , and found a higher rate of recurrence. We identified three candidate genes, LOC100505811, TRAM2-AS1, and NPIPA1 with enrichment of somatic mutations compared to germline variants in intronic splicing motifs in at least three samples (7.1% -11.1% of the cohort, Supplemental Figures S8A-C, respectively). Eleven additional genes were recurrent in at least 2 samples (4.7% of the cohort, Table 1 ).
Splicing Motif Mutations Lead to Functional Changes in Alternative Splicing
With RNA-seq data available for 25 of the 42 samples, we analyzed the TCGA GBM dataset further. Each of the recurrent mutations identified in GBM occurred at highly conserved positions within the splicing motif and either substituted a nucleotide that was not normally observed at that position We continued to examine the neuroblastoma splicing motif mutations in MOXD2P and CGB7, along with the NPIPA1 (chr16:15040359) and TRAM2-AS1 splicing motif mutations identified in GBM. We cloned these introns containing the mutations into the pGINT splicing reporter where the introns separated the eGFP coding sequence into two exons, and we used qPCR to empirically assess canonical splicing efficiencies in SHEP human neuroblastoma cells after a 16 hour transfection. We compared introns containing the wild-type allele, the splicing motif mutation, and a control mutation that converted the AG dinucleotide at the 3' splice site to a GG dinucleotide. We hypothesized that introduction of the mutant allele in the splicing motif would alter the ability of the cells to efficiently splice the eGFP exons, with the control mutation eliminating canonical splicing altogether.
The MOXD2P splicing motif mutations at chr7:141943454 (A>C) and chr7:141944631 (C>T) are located 47 bp and 149 bp from the nearest intron-exon boundary, respectively. These mutant alleles led to 3-fold and 2-fold increases in splicing efficiency, respectively, when compared to the wild-type alleles (G>C), however, did not lead to a statistically significant change in splicing efficiency, despite residing only 18 bp away from the nearest intron-exon boundary ( Figure 5C ).
The G>A mutation at chr16:15040359 within NPIPA1 resides 520 bp away from the nearest intron-exon boundary in an intron approximately 3 kb in total length. This mutation led to a 14% increase of canonical splicing efficiency when compared to the wild-type allele ( Figure 5D , p=0.0478). Similarly, the T>G mutation at chr6:52445058 within TRAM2-AS1 is located 650 bp away from the nearest intron-exon boundary in a 3.3 kb intron. The mutant allele led to a decrease in splicing efficiency, resulting in 56% of the splicing efficiency of wild-type allele ( Figure 5E , p=0.0375). All splicing reporters with a splice-site mutation had undetectable eGFP expression. These results confirm that splicing motifs, even when located beyond immediate exon-intron boundaries, can function to influence alternative splicing. It should be noted that enhancement or reduction in splicing efficiency was not associated directionally with either gain-of-function or loss-of-function mutations; this can be attributed to the creation of a match to a splicing motif could increase the affinity for either splicing silencers or splicing enhancers.
Similarly, a mutation that destroys a match to a splicing motif could decrease the affinity for either silencers or enhancers, leading to unpredictable splicing effects.
Recurrent Splicing Motif Mutations Identify Novel Genes of Interest in Neuroblastoma
Given the genome-wide somatic mutation rates in these WGS cohorts (2.685/Mb and 6.082/Mb for neuroblastoma and GBM, respectively), the nucleotide-level recurrence of splicing motif mutations suggests a high degree of selection whereby these altered splicing profiles contribute to the development of disease. Three genes (NPIPA1, DYNLRB1, and AIMP1) had enriched splicing motif mutations in both neuroblastoma and GBM (Table 1) , but these genes lacked research establishing their involvement in either disease and highlighted the need for further investigation. While NPIPA1, nuclear pore complex interacting protein family--member A1, has an unknown function, both DYNLRB1 and AIMP1 encode proteins implicated in the pathogenesis of other cancers. DYNLRB1, dynein light chain roadblock-type 1, interacts with TGFβ signaling and is mutated in human ovarian, colorectal, and gastric cancers (41) . Interestingly, in ovarian cancer, novel splice isoforms have been identified, the products of which result in a reduction in TGFβ signaling (42) . Functional studies also implicate a role for DYNLRB1 in cell migration. AIMP1, aminoacyl tRNA synthetase complex-interacting multifunctional protein 1, is an intracellular protein that is subject to proteolytibc cleavage when present at the cell surface. Upon cleavage, the released 22 kDa peptide induces apoptosis, antagonizes angiogenesis, and can stimulate an inflammatory response in the tumor microenvironment. In contrast, at high intracellular concentrations, AIMP1 induces cell migration (43).
Although we can examine the genomic effects of these mutations with regards to splicing motifs, we cannot categorically define these as gain-of-or loss-of-function at the gene or protein level. As the results from our splicing reporter assays suggest, both the creation of and destruction of splicing motifs could facilitate and impair splicing, depending on the binding of splicing enhancers or splicing silencers.
The introns containing the splicing motif mutations in DYNLRB1 and AIMP1 spanned over 8 kb and 10 kb, respectively, making them unamenable to in vitro splicing reporter assays. Additionally, any specific effects on splicing are not necessarily predictive of downstream gene function, as alternatively spliced variants could have no function or are immediately degraded by nonsense mediated decay (possibly leading to no effect or haploinsufficiency), act as a dominant negative, or even show constitutive activity.
Research. , Figure 6E ; p=N.S., Figure 6F ). These data suggest that splicing motif mutations undergo selection in genes with clinical relevance and can be useful to identify novel targets in disease.
Discussion
In this study we leveraged a mouse genetic system to decode and map genetic regulation of splicing.
We identified over 2500 putative sQTL, consistent with alternative splicing being subject to a greater degree of genetic control (16) than indicated by the earliest studies (<400 sQTL) (11) (12) (13) (14) . Furthermore, by using the TH-MYCN neuroblastoma mouse model, we were able to examine splicing in somatic tissue during the course of neuroblastoma development and oncogenic overexpression. Although several splicing factors are known direct targets of MYC, we have observed no changes in transgene expression between the parental strains, suggesting genetic differences between strains are the primary drivers of the sQTL. As the conservation of splicing between mouse and human has been estimated to be up to 87% (37), we looked to see if our results could have relevance in a human setting.
With the growing appreciation that alternative splicing can play functional roles in cancer, splicing factors have garnered considerable interest as potential targets for therapy (6) . In this regard, our analysis enabled us to focus on only a few genes in each region. Although this analysis was limited by relatively large 95% confidence intervals stemming from the backcrossed nature of our cohort, we were nevertheless able to utilize this approach to identify critical loci harboring genes previously unknown to affect splicing. We did not find a high degree of trans-sQTL co-localization, sites that might be indicative of splicing master regulators. This could reflect a rarity of such trans-sQTL overall, or might alternatively be attributed to a limitation within our system, as polymorphisms in such a critical component of the splicing process might not be tolerated in either strain. Our analysis reveals an abundance of transacting genes that influence splicing and act in a limited gene-to-gene scope in a highly tissue specific fashion. While the genes we have identified could act as bone fide splicing factors and bind directly to RNA or the spliceosome, they could also act indirectly by affecting the expression or activity of other splicing factors. Nevertheless, these data suggest a greater complexity to the splicing pathway than what has been already defined by mass spectrometry experiments focused on the spliceosome (44) . It should be noted that our trans-sQTL analysis is not comprehensive; by specifically examining genes within the confidence interval that are differentially expressed between tissues, we were not able to identify genes with activities that are modified by post-translational modifications and microRNAs that could regulate the expression of other splicing factors.
FUBP1 has been reported to be a tumor suppressor (28) and an oncogene (45) with the ability to both activate and repress MYC transcription (46) . The strain-specific splicing we observe suggests distinct functions for alternatively spliced FUBP1 isoforms. Of the two triplet splicing products, FUBP1
97-led to an increase of MYC whereas FUBP1 97S reduced MYC levels. Our RNA-seq-based survival analysis ( Figure   3D ) represented an interim analysis of the TARGET program and is currently under-powered to examine the relationship between isoform expression and disease stage. These data raise the possibility that 
analysis of intronic splicing enhancers utilized a splicing reporter construct to test the effects of random decamers inserted into the intron (47) . Our unbiased analysis is the first of which we are aware to identify recurrent intronic splicing motifs in vivo.
We identified and established relevance for these splicing motifs by analyzing WGS from two different human tumor types, identifying novel candidate genes with functional implications in the process. The TCGA WGS cohort provided us with additional insights into the effects of these mutations, as a portion of the samples were accompanied by RNA-seq data. Despite this, not all samples had both transcriptomic and genomic data available, limiting our analysis of normalized exon expression for the NPIPA1 splicing motif mutation to just three tumors. Nevertheless, four out of five in vitro splicing reporters containing these introns with splicing motif mutations confirm functional significance, showing that even single nucleotide changes hundreds of bases away from the nearest intron-exon boundary could impact mRNA splicing. These splicing motifs may function to bind accessory splicing factors to promote exon skipping, enhance exon inclusion, or even drive truncated transcripts through intronretention or alternative polyadenylation. They may also alter splicing by changing the transcript's secondary structure; without highly accurate RNA folding predictions, this analysis remains challenging and uncertain. It is also possible that these splicing motifs reside in non-coding RNA, which could in turn regulate expression of splicing factors.
The recurrent somatic mutations we identified in neuroblastoma and GBM might be easily dismissed due to their intronic nature, but our analysis extends understanding of the cancer genome by identifying functional ramifications for these intronic sites. The somatic mutations we identify within splicing motifs represent just one avenue whereby cancers may benefit from the deregulation of these gene products. Our analysis also broadens the applicability of these data beyond the limited individuals who 
Methods

Generation of a heterogeneous cohort backcrossed mice
Mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and were housed and treated following UCSF IACUC guidelines. FVB/NJ mice transgenic for TH-MYCN were bred to wild-type 129/SvJ mice. Transgenic animals from the resulting F1 generation were identical genetically, possessing an allele for each gene from both parental strains. F1 mice were then backcrossed to 129/SvJ mice to generate the N1 generation used in this analysis. Superior cervical ganglia (SCG) and cerebellum (CB)
were surgically isolated and snap-frozen in liquid nitrogen (n=102).
Genotyping
DNA was isolated from spleen tissue using a proteinase K lysis followed by phenol chloroform extraction. Microsatellite marker genotyping was carried out by the Marshfield Clinic (Marshfield, WI), and CIDR (Baltimore, MD). SNP genotyping was performed using template-directed primer extension 
Expression Arrays
1 μg of RNA was used as a starting template for RiboMinus rRNA subtraction (Invitrogen/Life Technologies) followed by the ST labeling protocol (Affymetrix, Santa Clara, CA). Labeled samples were hybridized to Affymetrix Mouse Exon 1.0 arrays. Arrays were normalized using RMA in the XPS Bioconductor package within R at both the exon level and the transcript level using core probes.
Differential expression between tissue types at the transcript level was examined using Significance Analysis of Microarrays (SAM) (48) .
sQTL Analysis
Exon expression was normalized to gene expression by calculating normalized exon expression, a ratio of exon expression to gene expression (both values determined using the XPS Bioconductor package). sQTL were calculated using normalized exon expression as a quantitative trait in eQTL software as previously described (49) . Briefly, linkage between normalized exon expression and loci was assessed by linear regression with genome-wide significance determined using an FDR < 0.05. Due to the ability of exonic polymorphisms to function as ESEs or ESSs, we did not exclude exons that harbored SNPs between the two strains. Trans-sQTL were drawn using Circos (50) . LOD scores and related confidence intervals were drawn and calculated using the R-QTL package within R.
Mouse WGS Analysis
FVB/NJ and 129/SvJ whole-genome sequencing data were downloaded from the ENA (Accession: ERP000687) and SRA (Accession: SRX205921), respectively, as raw FASTQ files. Reads were mapped to the reference genome (mm9) using Bowtie2 (v. 2.1.0) using the "-fast-local" preset. Genotypes were called using the GATK UnifiedGenotyper package (v. 2.4-9). SNPs were compared using the VCFtools package (v. 1.10). Consensus sequences for both strains were generated using the samtools mpileup 
Splicing Motifs
Spliced exons were identified as possessing a cis-sQTL in both tissues, and the direction of splicing in each strain was noted. 19-mer sequences surrounding polymorphic nucleotides and their positions relative to the spliced exon were acquired in the direction of transcription from consensus FASTA sequences generated from strain-specific WGS. Sequences were trimmed to exclude exonic bases, and regions where either strain returned a poly(N) motif indicative of a lack of sequencing coverage were discarded. Extracted sequences were binned based on the direction of the associated splicing and their origin (5' intron or 3' intron). MEME (52) was used to identify recurrent motifs with a width of at least 10 bases in these bins using a background GC content of 42%. Motifs with an E-Value < 0.05 and derived from at least 20 sequences were reported as significant. Redundant motifs were identified as those that shared a Pearson correlation coefficient > 0.60, and the representative motif was chosen with the lowest E-Value. TOMTOM (52) was used to compare sets of identified motifs at an FDR < 0.05 using Pearson correlation coefficients and requiring a minimum overlap of five bases. Cumulative matching of splicing motifs were determined by generating a multi-FASTA file consisting of 1,048,576 possible decamer permuations.
743, or 0.07% of these sequences matched the splicing motifs when compared to this file using MAST Single-nucleotide variants (SNVs) were detected with MuTect, a Bayesian framework for the detection of somatic mutations (53) . Somatic and germline SNVs were filtered according to MuTect defaults (germline variants were kept at a LOD(N) threshold of 2.3). SNVs for TCGA GBM samples aligned to hg18 were converted to hg19 coordinates using the UCSC liftover tool (54). For technical reasons, one GBM sample only had SNV calls from chromosomes 1-7, and another GBM sample only had SNV calls from chromosomes 1-12. The overall somatic mutation rates were calculated by dividing the total number of somatic mutations by the total number of "callable bases" identified by MuTect. The GBM samples with missing SNV calls were omitted from the calculation of somatic mutation rates.
Intronic sequences were extracted from the hg19 reference genome encompassing 9 bp upstream and downstream of the identified in the 5'-3' direction of transcription. Reference sequences in addition to sequences containing the alternative allele were analyzed for splicing motif occurrences using MAST at a sequence p-value threshold of 0.0001, recording the best motif match to either the reference or alternative sequence as determined by the lowest sequence p-value. 100-bp paired end reads were first aligned to the reference human genome (hg19) using spliced read mapper Tophat 2.0.8 (57). We then used Cufflinks 2.1.1 (58) for gene abundance estimation.
Abundances in fragments per kilobase of exon per million fragments mapped (FPKM) were calculated for each annotated RefSeq gene. Kaplan-Meier analysis was performed using GraphPad Prism. High and low distal:proximal isoform ratios were determined by a median split. Significance was determined by the Log-rank test.
Splicing Reporters
The region of interest from NPIPA1 was PCR-amplified using AccuPrime Taq High Fidelity (Invitrogen/Life Technologies) from genomic DNA obtained from HEK293T cells using gNPIPA1, gTRAM2-AS1, gMOXD2P, gCGB7 Cloning-F and Cloning-R primers (Integrated DNA Technologies (IDT), Coralville, Iowa, Supplemental Table 8 ) and TOPO-cloned into the PCR2.1-TOPO vector (Invitrogen/Life Technologies).
The pGINT fluorescent splicing reporter was obtain from Addgene (Cambridge, MA, Plasmid 24217) and used as a template for PCR amplification of the GFP exons using the GFPEX1-F/R and GFPEX2-F/R primers (IDT) and Phusion High-Fidelity PCR Master Mix (Thermo Scientific) according to manufacturer's instructions. GFP fragments containing specific introns were generated via PCR using the GFPEX1-F, GFPEX2-R, and the appropriate Intron-F/R primer pair (IDT). The GFP fragment containing the second MOXD2P intron (containing the chr7:141944631 mutation) was generated through PCR amplification of the MOXD2P-2 gBLOCK (IDT) and GFP Exon 2, using the GFPEX1-F, GFPEX2-R and the Phusion High- 
Biosciences, Boston, MA). Reactions were run in triplicate on an ABI 7900HT Fast Real-Time PCR system (Applied Biosystems/Life Technologies) and analyzed using SDS 2.3 software. Splicing efficiency was calculated using the ∆∆CT method, comparing GFP expression to the expression of the Neomycin resistance gene included on the pGINT plasmid to control for plasmid copy number.
Tissue Culture
All cell lines were obtained from the UCSF Cell Culture Facility but not reauthenticated by the authors.
SHEP cells were grown in RPMI-1640 supplemented with 10% FBS. SK-N-AS and HEK293T cells were grown in DMEM supplemented with 10% FBS, non-essential amino acids, and sodium pyruvate. All cell lines were maintained at 37 Degrees with 5% CO 2 and tested for mycoplasma contamination by PCR.
Lentiviral Transduction
Human 
Neuroblastoma Expression Profiling and Survival Analysis
Survival data were obtained from two datasets on the R2: microarray analysis and visualization platform (59). The Versteeg dataset (31) (GEO Accession ID: GSE16476) spanned all neuroblastoma stages and included 88 samples profiled on Affymetrix U133P2 expression arrays. The Seeger dataset (32) (GEO Accession ID: GSE3446) included 102 primary untreated neuroblastoma tumors without MYCN gene amplification profiled on Affymetrix HG-U133A and HG-U133B platforms. Expression data for both datasets were calculated using the MAS 5.0 algorithm. FUBP1, DYNLRB1, AIMP1, and NPIPA1 expression were assayed using the following probes: 214093_s_at, 217918_at, 202542_s_at, and 214870_x_at.
High and low expression groups were separated by scanning along the cohort with a minimum size of 8.
Significance was assessed by the Log-Rank test. The false discovery rate was determined by the associated Q-Value.
Western Blotting
Cell lysate was harvested using Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA) supplemented with protease inhibitor (Roche, Basel, Switzerland) and 1% SDS. Protein was quantitated with the BCA assay kit (Pierce Biotechnology, Rockford, IL). Equal amounts of total protein were loaded and run on 4%-12% SDS-polyacrylamide gels (Invitrogen/Life Technologies) and transferred to PVDF membranes using the iBlot (Invitrogen/Life Technologies). After blocking (1 hour @ RT, 5% non-fat milk in TBS-T), membranes were incubated overnight (4 degrees, 5% BSA in TBS-T) with V5-specific antibody (1:5000, Invitrogen/Life Technologies), GAPDH-specific antibody (1:10000, Millipore, Billerica, MA), or C-MYCspecific antibody (XRP, 1:1000, Cell Signaling Technology). Antibodies were detected with HRP-linked 
mouse or rabbit (Calbiochem/Millipore) secondary antibodies followed by enhanced chemilluminescence (Amersham/GE, Piscataway, NJ).
cDNA Synthesis and RT-PCR
cDNA synthesis was performed using SuperScript VILO MasterMix (Invitrogen/Life Technologies) according to the manufacturer's instructions. 1 μg of total RNA was used as starting material in the reverse transcriptase reaction.
RT-PCR to determine retention of FUBP1 Exon 5 and validate the alternative ASTN2 isoform was performed using GoTaq Green MasterMix (Promega, Madison, WI) in 25 ul reactions according to the manufacturer's instructions using 1 μL of cDNA and FUBP1-1F/FUBP1-7R or Astn2-F/R primers, respectively (IDT, Supplemental Table 8 ). PCR products were run on a 1.5% agarose gel and Sanger sequenced (Quintara Biosciences). Sequence analysis and chromatogram generation was performed with Geneious (Auckland, New Zealand).
Quantitative-RT-PCR was performed using 1 μL of a 1:10 dilution of cDNA using the KAPA SYBR FAST qPCR Kit (Kapa Biosystems) according to manufacturer's instructions and the appropriate primer sets (IDT, Supplemental Table 8 01-05) was used as a negative control. 140 pmol of siRNA was transfected into HEK293T cells using Lipofectamine 2000 for a period of 72 hours, after which RNA was harvested using Trizol.
cDNA was synthesized and RT-PCR was performed using primers C5 RT-F/RT-R and FBXW12 RT-F/RT-R (IDT, Supplemental Table 8 ). The targeted amplicons for C5 and FBXW12 spanned exons 4-21 and exons 4-10, respectively. Products were run on a 1.5% agarose gel, and bands indicating the molecular weight of the full-length isoform was excised. The remaining gel products were extracted using the GelExtraction kit (Qiagen) and re-amplified using the same primers. The final products were analyzed on a 2% agarose gel. Differentially expressed products were gel-extracted and TOPO cloned into PCR2.1-TOPO vectors (Invitrogen/Life Technologies). Products were identified by Sanger sequencing (Quintara Biosciences) using M13 Forward and M13 Reverse primers and matched to the genome using BLAT (60).
Genomic Coordinates
All genomic coordinates are representative of either mm9 or hg19 reference builds.
Statistical Analysis
All statistics were performed using the R Project for Statistical Computing unless otherwise noted.
Data Access
Backcross array data and genotyping data have been archived in the NCBI Gene Expression Omnibus (Accession: GSE55248).
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